EDAP TMS S.A. American Depositary Shares
FOCL
NASDAQ Global Market5.88
USD
+0.20
- -
CIK
0001041934
ISIN
US2683111072
CUSIP
268311107
Return %
Stock
S&P500
1Y
289.40
17.85
3Y
-34.59
64.56
5Y
-3.29
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ryan Rhodes
- Full Time Employees
- 289
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Parc d’Activites la Poudrette-Lamartine Vaulx-en-Velin ARA France 69120
- IPO Date
- Aug 1, 1997
- CIK
- 0001041934
- Website
- focalone.com
- Similar Companies
- Business
- EDAP TMS S.A. American Depositary Shares (FOCL) company description EDAP TMS S.A. is a France-based medical device company that designs, develops, manufactures, and commercializes robotic energy-based therapies for minimally invasive urology, oncology, and related indications. The company principally focuses on high-intensity focused ultrasound (HIFU) technology to treat organ-confined prostate cancer and other clinical conditions, complemented by its lithotripsy and ESWL capabilities for urinary tract stone management. EDAP TMS operates through two main divisions: HIFU, which includes robotic HIFU systems and associated disposables, maintenance, and service offerings; and ESWL/lithotripsy, which provides noninvasive stone-treatment solutions. The core products include Ablatherm Fusion and Focal One robotic HIFU systems, along with ancillary components, consumables, and service contracts; and complementary urinary stone management equipment and consumables. The company markets its devices and services through direct sales, distributors, and leasing arrangements to hospitals, clinics, and ambulatory surgery centers in multiple regions. Founding year and headquarters: established in 1992; headquartered in Lyon, France. EDAP TMS maintains a global footprint with commercial and distribution operations across Europe, the Americas, the Middle East, and Asia-Pacific regions, and maintains subsidiaries and partners to support regional sales, training, service, and regulatory compliance. The company actively pursues strategic partnerships, regulatory clearances, and product enhancements to expand its HIFU and ESWL offerings and geographic reach, including collaborations with clinical research groups and health care providers to extend adoption of focal therapy approaches and noninvasive stone management solutions. EDAP TMS also engages in funding activities, including public offerings and financing arrangements to support product development, regulatory submissions, and global market expansion. Industry and segments: medical devices and robotic energy-based therapies; primary business segments include HIFU systems (Ablatherm Fusion, Focal One) for focal therapy in urology and other potential oncologic applications, disposables and service packages, ESWL/Lithotripsy devices, and related clinical services. Target markets include hospitals, cancer centers, urology clinics, and specialty surgical centers in North America, Europe, and additional international markets. Subsidiaries and corporate relationships: maintains a network of international subsidiaries and distribution partners; engages in collaborations and potential corporate restructurings in line with regulatory approvals and market strategy. Recent developments in the last 1–2 years encompass regulatory advancements, product line expansions, strategic partnerships, potential capital-raising activities, and ongoing geographic expansion efforts to broaden adoption of Focal One and other HIFU solutions. Note: The above description reflects EDAP TMS S.A. as the issuer of FOCL ADSs and summarizes core products, services, geography, and strategic activities based on publicly available information up to the current period. For the most current and precise disclosures, refer to EDAP TMS S.A. investor materials, regulatory filings, and official company communications.
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical